- Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
- Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
- First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
- Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
- Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024
- Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
More ▼
Key statistics
As of last trade, Kyverna Therapeutics Inc (KYTX:NSQ) traded at 9.62, 42.44% above the 52 week low of 6.75 set on Jun 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.63 |
---|---|
High | 10.00 |
Low | 9.13 |
Bid | 9.59 |
Offer | 9.65 |
Previous close | 9.71 |
Average volume | 510.13k |
---|---|
Shares outstanding | 43.12m |
Free float | 38.47m |
P/E (TTM) | -- |
Market cap | 418.65m USD |
EPS (TTM) | -1.73 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 20:34 BST.
More ▼